CD20 expression in B-cell precursor acute lymphoblastic leukemia is common in Mexican patients and lacks a prognostic value

Solano-Genesta, Manuel; Tarín‐Arzaga, Luz; Velasco-Ruiz, Ileana; Lutz‐Presno, Julia; González-Llano, Óscar; Mancı́as-Guerra, Consuelo; Rodríguez-Romo, Laura; Ruíz-Delgado, Guillermo J.; Ruíz‐Argüelles, Guillermo J.; Jaime‐Pérez, José Carlos; Gómez‐Almaguer, David

doi:10.1179/102453312x13221316477741

Cited by 11 publications

(20 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[6][7][8][9][10][11] All researches reported the prognostic significance of CD20 expression status for survival in pediatric BCP-ALL. Of these studies, 18 studies that did not provide survival information or only dealing with adult BCP-ALL were subsequently excluded.…”

Section: Resultsmentioning

confidence: 99%

“…Of these studies, 18 studies that did not provide survival information or only dealing with adult BCP-ALL were subsequently excluded. 10 All studies provided OS or EFS directly or indirectly and were included in the meta-analysis finally. [6][7][8][9][10][11] All researches reported the prognostic significance of CD20 expression status for survival in pediatric BCP-ALL.…”

Section: Resultsmentioning

confidence: 99%

“…[6][7][8][9][10][11] Three studies indicated that CD20 status did not correlate with minimal residual disease at the end of induction treatment, which was known to be associated with adverse prognosis. [6][7][8][9][10][11] Three studies indicated that CD20 status did not correlate with minimal residual disease at the end of induction treatment, which was known to be associated with adverse prognosis.…”

Section: Resultsmentioning

confidence: 99%

“…[9][10][11] Two researches informed that none of the patients with MLL-AF4 gene rearrangements expressed CD20 (P = 0.01). 10 Overall, the pooled HR for OS was 0.70 (95% CI: 0.32-1.07), without any evidence for significant heterogeneity between studies (P = 0.247, I 2 = 0.262) (Fig. 8 Contrarily, in 1 study there was a significantly higher incidence of CD20 expression in male patients (P = 0.003) ( Table 3).…”

Section: Resultsmentioning

confidence: 99%

“…Hence, the exploration and identification of biomarkers with prognostic effect are necessary to improve outcome estimation. [8][9][10][11] The prognostic role of the CD20 expression level in childhood BCP-ALL remains a subject of debate. 2 To date, studies have mainly focused on adults.…”

mentioning

confidence: 99%

See 4 more Smart Citations

CD20 and Outcome of Childhood Precursor B-cell Acute Lymphoblastic Leukemia

Luo²,

Ou³

2015

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

CD20 is a B-cell differentiation antigen that is expressed variably in precursor B-cell acute lymphoblastic leukemia (BCP-ALL). The prognostic significance of CD20 expression in childhood BCP-ALL remains controversial. Some studies have demonstrated that CD20 overexpression correlates with worse survival in pediatric patients with BCP-ALL, but some other studies suggest a better outcome. To explore the prognostic role of high CD20 expression in pediatric BCP-ALL, we performed a meta-analysis of the previous studies that provided survival information according to CD20 expression status. Pooled hazard ratios (HRs) indicated that high CD20 expression had no inferior impact on the prognosis of pediatric BCP-ALL. The summary HR for overall survival was 0.70 and combined HR for event-free survival was 1.01. These findings suggest that high CD20 expression does not influence the outcome for pediatric BCP-ALL. CD20 may lack prognostic value in children with BCP-ALL.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

CD20 and Outcome of Childhood Precursor B-cell Acute Lymphoblastic Leukemia

Luo²,

Ou³

2015

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

show abstract

CD19 negative precursor B acute lymphoblastic leukemia (B‐ALL)—Immunophenotypic challenges in diagnosis and monitoring: A study of three cases

Ghodke

Bibi

Rabade

et al. 2016

Cytometry Part B Clinical

View full text Add to dashboard Cite

Background CD19 is a B‐cell specific marker, expressed on all stages of B‐lymphocytes including plasma cells. It is widely used in the flow cytometric immunophenotyping (FCI) of B‐cell and plasma cell malignancies. The analysis approach of FCI for the diagnosis and monitoring of B‐cell acute lymphoblastic leukemia (B‐ALL) is totally based on the CD19‐based primary gating strategy and it would be challenging to study B‐ALL without CD19 expression. Since CD19 negative B‐ALL are extremely rare, we report three cases of B‐ALL with negative expression of CD19 and discussed its implication in the diagnosis, residual disease monitoring and future targeted therapy. Methods Peripheral blood (PB) and bone marrow (BM) samples from three cases suspicious of acute leukemia were studied for morphology, cytochemistry, immunophenotyping and cytogenetics. FCI was performed using a comprehensive six to eight‐color multiparametric assay. The cytogenetic studies for standard recurrent genetic translocations were performed by FISH & Karyotyping. Results The three cases studied were diagnosed as B‐ALL based on the expression of CD10, CD20, CD22, CD34, and CD79a by leukemic blasts. CD19 was studied using two different clones (i.e. J3‐119 & HIB‐19) and found to be severely down regulated in all three cases. There were no significant differentiating features in morphology. Cytogenetic studies were negative for recurrent translocations. Conclusion We report three cases of extremely rare CD19 negative B‐ALL. Lack of awareness of negative CD19 expression in B‐ALL can leads to incorrect immunophenotypic diagnosis and monitoring of B‐ALL, especially in laboratories using limited markers. © 2016 International Clinical Cytometry Society

show abstract